Comments
Granules India Limited announced that the USFDA approved its Abbreviated New Drug Application (ANDA) for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg. These capsules serve various purposes, including the short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD) and risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcers in adults.
The approval contributes to the company’s growing ANDA portfolio, which now totals 62 approvals from the US FDA, including 60 final and 2 tentative approvals. With the current U.S. market for Esomeprazole Magnesium Delayed-Release Capsules estimated at approximately $168 Million, according to MAT Jul 2023, IQVIA/IMS Health, the approval marks a step forward for Granules India Limited.
However, the shares fell 0.83 per cent to ₹352.60 at 1 pm on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.